S&P 500   4,128.89 (-0.84%)
DOW   34,036.05 (-0.35%)
QQQ   305.53 (-1.40%)
AAPL   152.03 (-1.69%)
MSFT   269.93 (+0.89%)
META   185.54 (-3.17%)
GOOGL   99.56 (-7.51%)
AMZN   100.11 (-1.96%)
TSLA   199.37 (+1.30%)
NVDA   225.27 (+1.60%)
NIO   10.69 (-2.11%)
BABA   105.76 (+0.25%)
AMD   85.71 (-0.23%)
T   19.09 (-0.83%)
F   13.47 (+0.15%)
MU   60.67 (-2.35%)
CGC   2.78 (-1.42%)
GE   81.95 (-0.19%)
DIS   111.41 (-0.20%)
AMC   5.76 (-6.80%)
PFE   43.87 (+0.64%)
PYPL   80.36 (-3.45%)
NFLX   361.88 (-0.29%)
S&P 500   4,128.89 (-0.84%)
DOW   34,036.05 (-0.35%)
QQQ   305.53 (-1.40%)
AAPL   152.03 (-1.69%)
MSFT   269.93 (+0.89%)
META   185.54 (-3.17%)
GOOGL   99.56 (-7.51%)
AMZN   100.11 (-1.96%)
TSLA   199.37 (+1.30%)
NVDA   225.27 (+1.60%)
NIO   10.69 (-2.11%)
BABA   105.76 (+0.25%)
AMD   85.71 (-0.23%)
T   19.09 (-0.83%)
F   13.47 (+0.15%)
MU   60.67 (-2.35%)
CGC   2.78 (-1.42%)
GE   81.95 (-0.19%)
DIS   111.41 (-0.20%)
AMC   5.76 (-6.80%)
PFE   43.87 (+0.64%)
PYPL   80.36 (-3.45%)
NFLX   361.88 (-0.29%)
S&P 500   4,128.89 (-0.84%)
DOW   34,036.05 (-0.35%)
QQQ   305.53 (-1.40%)
AAPL   152.03 (-1.69%)
MSFT   269.93 (+0.89%)
META   185.54 (-3.17%)
GOOGL   99.56 (-7.51%)
AMZN   100.11 (-1.96%)
TSLA   199.37 (+1.30%)
NVDA   225.27 (+1.60%)
NIO   10.69 (-2.11%)
BABA   105.76 (+0.25%)
AMD   85.71 (-0.23%)
T   19.09 (-0.83%)
F   13.47 (+0.15%)
MU   60.67 (-2.35%)
CGC   2.78 (-1.42%)
GE   81.95 (-0.19%)
DIS   111.41 (-0.20%)
AMC   5.76 (-6.80%)
PFE   43.87 (+0.64%)
PYPL   80.36 (-3.45%)
NFLX   361.88 (-0.29%)
S&P 500   4,128.89 (-0.84%)
DOW   34,036.05 (-0.35%)
QQQ   305.53 (-1.40%)
AAPL   152.03 (-1.69%)
MSFT   269.93 (+0.89%)
META   185.54 (-3.17%)
GOOGL   99.56 (-7.51%)
AMZN   100.11 (-1.96%)
TSLA   199.37 (+1.30%)
NVDA   225.27 (+1.60%)
NIO   10.69 (-2.11%)
BABA   105.76 (+0.25%)
AMD   85.71 (-0.23%)
T   19.09 (-0.83%)
F   13.47 (+0.15%)
MU   60.67 (-2.35%)
CGC   2.78 (-1.42%)
GE   81.95 (-0.19%)
DIS   111.41 (-0.20%)
AMC   5.76 (-6.80%)
PFE   43.87 (+0.64%)
PYPL   80.36 (-3.45%)
NFLX   361.88 (-0.29%)

Tandem Diabetes Care - TNDM Stock Forecast, Price & News

$43.44
-0.62 (-1.41%)
(As of 02/8/2023 12:27 PM ET)
Add
Compare
Today's Range
$43.00
$44.65
50-Day Range
$39.36
$46.50
52-Week Range
$33.51
$124.03
Volume
153,740 shs
Average Volume
942,755 shs
Market Capitalization
$2.79 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$75.50

Tandem Diabetes Care MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.56 Rating Score
Upside/​Downside
73.8% Upside
$75.50 Price Target
Short Interest
Bearish
8.10% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.64
Upright™ Environmental Score
News Sentiment
1.64mentions of Tandem Diabetes Care in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$402,500 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.77) to ($0.48) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.36 out of 5 stars

Medical Sector

202nd out of 1,029 stocks

Surgical & Medical Instruments Industry

17th out of 105 stocks

TNDM stock logo

About Tandem Diabetes Care (NASDAQ:TNDM) Stock

Tandem Diabetes Care, Inc. engages in the design, development, and commercialization of products for people with insulin-dependent diabetes. Its flagship product, t:slim X2 Insulin Delivery System, operates as a small insulin pump. The company was founded by Paul M. DiPerna on January 27, 2006, and is headquartered in San Diego, CA.

Receive TNDM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tandem Diabetes Care and its competitors with MarketBeat's FREE daily newsletter.

TNDM Stock News Headlines

Without Graphite, There Would Be ZERO EV Batteries!
Investors constantly hear that lithium is the key to powering the transition to green energy. Truth is, today's EV batteries contain more graphite in volume than any other essential ingredients.
Tandem Diabetes Care Reports Q4 Preliminary Sales
Without Graphite, There Would Be ZERO EV Batteries!
Investors constantly hear that lithium is the key to powering the transition to green energy. Truth is, today's EV batteries contain more graphite in volume than any other essential ingredients.
Tandem (TNDM) to Expand Global Insulin Pump Base With New Buy
Tandem Diabetes Care: Undervalued Technology Leader
Tandem Diabetes (TNDM) Q3 Earnings Miss, Sales View Cut
Barclays Keeps Their Buy Rating on Tandem Diabetes Care (TNDM)
Tandem Diabetes Shares Slump After Dismal Annual Outlook
See More Headlines
Receive TNDM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tandem Diabetes Care and its competitors with MarketBeat's FREE daily newsletter.

TNDM Company Calendar

Last Earnings
11/03/2021
Today
2/08/2023
Next Earnings (Confirmed)
2/22/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TNDM
Fax
N/A
Employees
2,000
Year Founded
2006

Price Target and Rating

Average Stock Price Forecast
$75.50
High Stock Price Forecast
$130.00
Low Stock Price Forecast
$43.00
Forecasted Upside/Downside
+73.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.56
Research Coverage
9 Analysts

Profitability

Net Income
$15.57 million
Pretax Margin
-8.30%

Debt

Sales & Book Value

Annual Sales
$702.80 million
Cash Flow
$0.52 per share
Book Value
$6.82 per share

Miscellaneous

Free Float
62,884,000
Market Cap
$2.79 billion
Optionable
Optionable
Beta
0.79

Social Links


Key Executives

  • John F. SheridanJohn F. Sheridan
    President, Chief Executive Officer & Director
  • David B. Berger
    Chief Operating Officer, EVP & Assistant Secretary
  • Leigh A. VossellerLeigh A. Vosseller
    CFO, Treasurer, Principal Accounting Officer & EVP
  • Manuel Jaime
    Senior Vice President-Technology & Digital Health
  • Michael Michaud
    Vice President-Research & Development













TNDM Stock - Frequently Asked Questions

Should I buy or sell Tandem Diabetes Care stock right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Tandem Diabetes Care in the last year. There are currently 4 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" TNDM shares.
View TNDM analyst ratings
or view top-rated stocks.

What is Tandem Diabetes Care's stock price forecast for 2023?

9 Wall Street analysts have issued 12-month target prices for Tandem Diabetes Care's stock. Their TNDM share price forecasts range from $43.00 to $130.00. On average, they predict the company's share price to reach $75.50 in the next year. This suggests a possible upside of 71.4% from the stock's current price.
View analysts price targets for TNDM
or view top-rated stocks among Wall Street analysts.

How have TNDM shares performed in 2023?

Tandem Diabetes Care's stock was trading at $44.95 at the beginning of 2023. Since then, TNDM stock has decreased by 2.0% and is now trading at $44.06.
View the best growth stocks for 2023 here
.

When is Tandem Diabetes Care's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 22nd 2023.
View our TNDM earnings forecast
.

How can I listen to Tandem Diabetes Care's earnings call?

Tandem Diabetes Care will be holding an earnings conference call on Wednesday, February 22nd at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were Tandem Diabetes Care's earnings last quarter?

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) issued its quarterly earnings data on Wednesday, November, 3rd. The medical device company reported $0.09 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.08 by $0.01. The medical device company had revenue of $179.63 million for the quarter, compared to analysts' expectations of $172.80 million. Tandem Diabetes Care had a negative net margin of 8.59% and a negative trailing twelve-month return on equity of 8.34%. During the same period last year, the company earned ($0.09) earnings per share.

When did Tandem Diabetes Care's stock split?

Tandem Diabetes Care shares reverse split on the morning of Tuesday, October 10th 2017. The 1-10 reverse split was announced on Monday, October 9th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Monday, October 9th 2017. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What guidance has Tandem Diabetes Care issued on next quarter's earnings?

Tandem Diabetes Care issued an update on its fourth quarter 2022 earnings guidance on Tuesday, January, 10th. The company provided EPS guidance of for the period. The company issued revenue guidance of $224.00 million-$224.00 million, compared to the consensus revenue estimate of $221.56 million.

What is John Sheridan's approval rating as Tandem Diabetes Care's CEO?

11 employees have rated Tandem Diabetes Care Chief Executive Officer John Sheridan on Glassdoor.com. John Sheridan has an approval rating of 88% among the company's employees.

What other stocks do shareholders of Tandem Diabetes Care own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tandem Diabetes Care investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Alibaba Group (BABA), Micron Technology (MU), DexCom (DXCM), Netflix (NFLX), Block (SQ), Roku (ROKU), Lululemon Athletica (LULU) and PayPal (PYPL).

What is Tandem Diabetes Care's stock symbol?

Tandem Diabetes Care trades on the NASDAQ under the ticker symbol "TNDM."

Who are Tandem Diabetes Care's major shareholders?

Tandem Diabetes Care's stock is owned by many different retail and institutional investors. Top institutional investors include Stephens Investment Management Group LLC (1.53%), New York State Common Retirement Fund (0.58%), Chicago Capital LLC (0.51%), Peregrine Capital Management LLC (0.29%), Essex Investment Management Co. LLC (0.28%) and WCM Investment Management LLC (0.23%). Insiders that own company stock include Brian B Hansen, Brian B Hansen, Christopher J Twomey, Christopher J Twomey, David B Berger, Dick Allen, Elizabeth Anne Gasser, James Leal, John F Sheridan, Kathleen Mcgroddy-Goetz, Kim D Blickenstaff, Leigh Vosseller, Mark Reinstra, Rebecca B Robertson, Rebecca B Robertson and Susan Morrison.
View institutional ownership trends
.

How do I buy shares of Tandem Diabetes Care?

Shares of TNDM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Tandem Diabetes Care's stock price today?

One share of TNDM stock can currently be purchased for approximately $44.06.

How much money does Tandem Diabetes Care make?

Tandem Diabetes Care (NASDAQ:TNDM) has a market capitalization of $2.83 billion and generates $702.80 million in revenue each year. The medical device company earns $15.57 million in net income (profit) each year or ($1.07) on an earnings per share basis.

How many employees does Tandem Diabetes Care have?

The company employs 2,000 workers across the globe.

How can I contact Tandem Diabetes Care?

Tandem Diabetes Care's mailing address is 11075 ROSELLE STREET, San Diego CA, 92121. The official website for the company is www.tandemdiabetes.com. The medical device company can be reached via phone at (858) 366-6900 or via email at smorrison@tandemdiabetes.com.

This page (NASDAQ:TNDM) was last updated on 2/8/2023 by MarketBeat.com Staff